Fundamentals-based quality & risk · not a recommendation
Raw blend 56 capped to 40 by a red flag.
Raw blend 56 → capped to 40
Indo US Bio-Tech Ltd scores 40/100 (Caution) on the Orion Score — moderate business quality (56), weak growth (47) and moderate balance-sheet safety (63). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
18/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q3 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q3 2026 | ₹22.8 | ₹3 | 17.2% | ₹1.49 |
| Q2 2026 | ₹30.85 | ₹3.45 | 12.8% | ₹1.72 |
| Q1 2026 | ₹30.77 | ₹4.7 | 17.1% | ₹2.35 |
| Q4 2025 | ₹33.38 | ₹3.68 | 12.6% | — |
| Q3 2025 | ₹23.56 | ₹5.05 | 22.8% | ₹2.52 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹103.84 | ₹16.27 | ₹19.06 | 17.3% |
| FY 2024 | ₹72.84 | ₹8.24 | ₹11 | 14.2% |
| FY 2023 | ₹61.74 | ₹7.24 | ₹9.34 | 13.9% |
| FY 2022 | ₹50.06 | ₹5.06 | ₹6.9 | 13.3% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| INDOUS ★ | ₹196 Cr | 14.94 | 22.10% | 16.90% | 0.32x | 17.22% |
| HINDUNILVR | ₹4,98,466 Cr | 46.95 | 21.37% | 21.60% | 0.03x | 21.55% |
| BRITANNIA | ₹1,28,937 Cr | 50.94 | 57.77% | 53.31% | 0.27x | 16.38% |
| COLPAL | ₹55,822 Cr | 42.37 | 103.69% | 81.59% | 0.03x | 29.98% |
| AWL | ₹24,574 Cr | 23.57 | 15.16% | 10.52% | 0.11x | 1.84% |
| CCL | ₹16,186 Cr | 41.49 | 20.46% | 18.00% | 0.56x | 12.36% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹97.84 | ₹84.46 | ₹69.47 | ₹55.62 |
| Equity | ₹78.52 | ₹62.75 | ₹54.5 | ₹38.51 |
| Total Debt | ₹14.84 | ₹14.32 | ₹11.6 | ₹12.84 |
| Cash | ₹0.25 | ₹1.1 | ₹0.19 | ₹0.05 |
| Net Debt | ₹14.59 | ₹13.23 | ₹11.41 | ₹12.79 |
| Working Capital | ₹70.39 | ₹54.23 | ₹47.62 | ₹34.55 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 75.65% ↑ | 0% | 0% | 24.35% ↓ |
| Q3 FY2026 | 70.18% | — | — | 29.83% |
| Q2 FY2026 | 70.18% | — | — | 29.83% |
| Q1 FY2026 | 70.18% | — | — | 29.83% |
| Q4 FY2025 | 70.18% | — | — | 29.83% |
| Q3 FY2025 | 70.18% | — | — | 29.82% |
| Q2 FY2025 | 70.18% | — | — | 29.83% |
| Q1 FY2025 | 70.18% | — | — | 29.82% |
No recent corporate actions
Ask: "Is Indo US Bio-Tech Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Indo US Bio-Tech Ltd is listed on the NSE under the Fast Moving Consumer Goods sector, Other Agricultural Products industry. ISIN: INE250Z01010. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.